|
시장보고서
상품코드
2076191
항체 시장 : 약제 유형별, 질환별, 최종사용자별 및 지역별Antibodies Market, By Drug Type, by Disease Indication By End User, And by Region |
||||||
항체 시장은 2026년에 3,230억 4,370만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 7,647억 1,480만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 13.1%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 3,230억 4,370만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 13.10% | 2033년 시장 규모 예측 : | 7,647억 1,480만 달러 |
항체는 암, 자가면역질환, 혈액질환, 감염증 등의 질환 치료에 활용되고 있습니다. 암 유병률의 증가는 시장내 제조업체의 성장에 유망한 기회를 창출할 것으로 예상됩니다. 항체 제제는 생물제제로 분류됩니다. 생물제제 제조사는 제품을 시장에 출시하기 전에 미국 식품의약국(FDA)으로부터 승인(의약품 승인과 동일)을 받아야 합니다. 다만, 의약품과 달리 생물제제의 경우, 생물제제 평가 연구 센터(CBER)에 생물제제 승인 신청(BLA)을 제출해야 합니다. 또한 각 정부 당국은 개혁을 추진함으로써 의약품 가격의 억제 및 인하에 주력하고 있습니다. 예를 들어 미국 정부는 2019년 2월, 제약사가 약국 혜택 관리자(PBM) 등 유통 채널 파트너와 체결하는 계약을 제한함으로써 메디케어에서 환자의 본인 부담금을 낮추고자 하고 있습니다(이러한 계약이 의약품 정가 상승의 한 원인이 되고 있습니다).
시장 역학
시장의 주요 기업이 제품 포트폴리오를 확대하기 위해 제휴 및 파트너십과 같은 비유기적 성장 전략을 점점 더 많이 채택하고 있는 점이, 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어 2020년 1월, 바이오의약품 기업인 MorphoSys AG는 다국적 제약 기업인 Incyte Corporation과 제휴를 맺고, CD19를 표적으로 하는 인간화 Fc 변형 단일클론 항체인 MorphoSys사의 타파시타맙의 개발 및 상용화에 착수했습니다.
본 조사의 주요 특징 :
- 이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 이 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 항체 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 세계의 항체 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 항체 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 항체 시장 : 약제 유형별, 2021-2033년
제5장 세계의 항체 시장 : 질환 적응증별, 2021-2033년
제6장 세계의 항체 시장 : 최종사용자별, 2021-2033년
제7장 세계의 항체 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.07.09Antibodies Market is estimated to be valued at USD 3,23,043.7 Mn in 2026 and is expected to reach USD 7,64,714.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 13.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,23,043.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.10% | 2033 Value Projection: | USD 7,64,714.8 Mn |
Antibodies are used in therapeutic applications for the treatment of diseases such as cancer, autoimmune diseases, hematological diseases, infectious diseases, and others. The increasing prevalence of cancer is expected to create lucrative opportunities for the growth of manufacturers in the market. Antibodies products come under biological therapeutic products. Biologic manufacturers require approval (similar to pharma drug approval) from the U.S. Food & Drug Administration prior to bringing the product to the market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Moreover, various government authorities are focused on controlling/lowering drug prices by adding reforms. For instance, the U.S. government is seeking to lower patients' out-of-pocket spending in Medicare by curbing deals that drug manufacturers make with its distribution channel partners such as pharmacy benefit managers, in February 2019 (these deals are responsible for increasing list price of drugs).
Market Dynamics
Increasing adoption of inorganic growth strategies, such as collaboration and partnership by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in January 2020, MorphoSys AG, biopharmaceutical company collaborated with Incyte Corporation a multinational pharmaceutical company for the development and commercialization of MorphoSys' tafasitamab, a humanized Fc-engineered monoclonal antibody against CD19.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antibodies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Key companies covered as a part of this study include Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antibodies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibodies market
Detailed Segmentation:
- Global Antibodies Market, By Drug Type (Revenue, USD Mn, 2021 - 2033)
- Monoclonal antibodies
- Polyclonal antibodies
- Antibody-drug complexes (ADCs)
- Global Antibodies Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
- CNS Disorders
- Cardiovascular Diseases
- Cancer
- Autoimmune Disorders
- COVID-19
- Others
- Global Antibodies Market, By End User (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Long-term Care Facilities
- Research institutes
- Global Antibodies Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- Company Profiles
- Novartis International AG*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Sanofi S.A.
- Eli Lilly and Co.
- Iovance Biotherapeutics, Inc.
- Ultragenyx Pharmaceutical Inc.
- Kyowa Kirin Co., Ltd.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product Launch
- Technological Advancements
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
4. Global Antibodies Market, By Drug Type, 2021-2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Polyclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Antibody-drug complexes (ADCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Antibodies Market, By Disease Indication, 2021-2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- CNS Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Antibodies Market, By End User, 2021-2033, (US$ Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segments Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Long-term Care Facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Research institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Antibodies Market, By Region, 2021-2033, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication , 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Novartis International AG*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson Services, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Iovance Biotherapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ultragenyx Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kyowa Kirin Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
